TY - JOUR
T1 - Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
AU - Takekuma, Munetaka
AU - Takahashi, Fumiaki
AU - Mabuchi, Seiji
AU - Kudaka, Wataru
AU - Horie, Koji
AU - Ikeda, Mariko
AU - Shikama, Ayumi
AU - Mitsuhashi, Akira
AU - Nagao, Shoji
AU - Suzuki, Shiro
AU - Mizuno, Mika
AU - Nishio, Shin
AU - Tokunaga, Hideki
AU - Ota, Yukinobu
AU - Kasamatsu, Takahiro
AU - Kitagawa, Ryo
AU - Toita, Takafumi
AU - Kobayashi, Hiroaki
AU - Ishikawa, Mitsuya
AU - Yaegashi, Nobuo
N1 - Funding Information:
This work was supported in part by the National Cancer Center Research and Development Fund of Japan (29-A-3) and by the Japan Agency for Medical Research and Development (AMED, JP18ck0106222 and JPP19ck0106513). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - Background: The aim of the current study was to evaluate oncologic outcomes of patients who were treated with salvage hysterectomy (HT), compared to systemic chemotherapy (CT) for persistent cervical cancer after definitive radiotherapy (RT)/ concurrent chemoradiotherapy (CCRT). Methods: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005 to 2014 were reviewed retrospectively (n = 317). Those who underwent a HT for persistent cervical cancer after definitive RT/CCRT were matched with propensity scores for patients who underwent systemic CT. Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. Results: A total of 142 patients with persistent cervical cancer after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). All background factors between HT and CT groups were well balanced. Median overall survival was 3.8 and 1.5 years in the HT and CT groups, respectively (p = 0.00193, hazards ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.73), Increasing residual tumor size was significantly associated with a high incomplete resection rate (p = 0.016, Odds Ratio 1.11, 95%CI 1.02–1.22). Severe late adverse events occurred in 7 patients (9.9%) in the HT cohort. Conclusion: The current study demonstrated that, when compared to systemic CT, the adoption of salvage HT for patients with persistent cervical cancer after definitive RT/CCRT reduced mortality rate by about 60%. This indicates that salvage HT could be curative treatment for those patients. Further prospective clinical trials with regard to salvage HT after RT/CCRT are warranted.
AB - Background: The aim of the current study was to evaluate oncologic outcomes of patients who were treated with salvage hysterectomy (HT), compared to systemic chemotherapy (CT) for persistent cervical cancer after definitive radiotherapy (RT)/ concurrent chemoradiotherapy (CCRT). Methods: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005 to 2014 were reviewed retrospectively (n = 317). Those who underwent a HT for persistent cervical cancer after definitive RT/CCRT were matched with propensity scores for patients who underwent systemic CT. Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. Results: A total of 142 patients with persistent cervical cancer after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). All background factors between HT and CT groups were well balanced. Median overall survival was 3.8 and 1.5 years in the HT and CT groups, respectively (p = 0.00193, hazards ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.73), Increasing residual tumor size was significantly associated with a high incomplete resection rate (p = 0.016, Odds Ratio 1.11, 95%CI 1.02–1.22). Severe late adverse events occurred in 7 patients (9.9%) in the HT cohort. Conclusion: The current study demonstrated that, when compared to systemic CT, the adoption of salvage HT for patients with persistent cervical cancer after definitive RT/CCRT reduced mortality rate by about 60%. This indicates that salvage HT could be curative treatment for those patients. Further prospective clinical trials with regard to salvage HT after RT/CCRT are warranted.
KW - Persistent diseases
KW - Radiotherapy
KW - Salvage hysterectomy
KW - Survival
KW - Uterine cervical Cancer
UR - http://www.scopus.com/inward/record.url?scp=85096941036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096941036&partnerID=8YFLogxK
U2 - 10.1186/s12885-020-07672-w
DO - 10.1186/s12885-020-07672-w
M3 - Article
C2 - 33256667
AN - SCOPUS:85096941036
SN - 1471-2407
VL - 20
JO - BMC cancer
JF - BMC cancer
IS - 1
M1 - 1169
ER -